BioMoti

BioMoti is dedicated to advancing biotechnology research, particularly in the field of engineering cancer therapeutics. BioMoti focuses on developing innovative solutions to address critical challenges in cancer treatment. The company is committed to improving patient outcomes through targeted and effective therapies.

Located at The QMB Innovation Centre, 42 New Road, London, E1 2AX, GB, BioMoti is at the forefront of developing a promising new class of drug-loaded particles designed to precisely target and gain entry to cancer cells. In the tumors, they slowly release drugs at the point of need while sparing healthy tissue. Early preclinical studies for BMT101, their lead ovarian cancer candidate, compared to the clinical standard of care, Taxol®, have shown very encouraging results including over 10-fold increases in drug concentration in tumors, 65-fold reductions in tumor burden, doubling of median survival and loss of toxicity.

BioMoti's mission is to transform cancer treatment through pioneering research and development. The company is always striving to refine its technologies and expand its impact on global health. We invite the management of BioMoti to create a customized and exclusive company showcase and product listing on our platform to further highlight your achievements and innovations.